Structure-function relationships in thrombin-activatable fibrinolysis inhibitor

Journal of Thrombosis and Haemostasis : JTH
Tom Plug, J C Meijers

Abstract

Thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator in the balance of coagulation and fibrinolysis. TAFI is a metallocarboxypeptidase that circulates in plasma as zymogen. Activated TAFI (TAFIa) cleaves C-terminal lysine or arginine residues from peptide substrates. The removal of C-terminal lysine residues from partially degraded fibrin leads to reduced plasmin formation and thus attenuation of fibrinolysis. TAFI also plays a role in inflammatory processes via the removal of C-terminal arginine or lysine residues from bradykinin, thrombin-cleaved osteopontin, C3a, C5a and chemerin. TAFI has been studied extensively over the past three decades and recent publications provide a wealth of information, including crystal structures, mutants and structural data obtained with antibodies and peptides. In this review, we combined and compared available data on structure/function relationships of TAFI.

References

Jan 1, 1989·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·A D Cardin, H J Weintraub
May 1, 1989·Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Für Klinische Chemie Und Klinische Biochemie·D HendriksM P Lommaert
Jun 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·D C ReesK D Hardman
Jun 16, 1995·The Journal of Biological Chemistry·L BajzarM E Nesheim
Jan 1, 1994·International Archives of Allergy and Immunology·T ShinoharaH Okada
Jan 29, 2000·The European Journal of Neuroscience·A MatsumotoR Matsumoto
Jun 28, 2000·Proceedings of the National Academy of Sciences of the United States of America·J L HarrisC S Craik
Feb 12, 2002·The Journal of Clinical Endocrinology and Metabolism·Yasuko HoriYasuhiro Sumida
Apr 10, 2002·Microbiology and Immunology·William D CampbellHidechika Okada
May 15, 2002·Microbiology and Immunology·Takeshi KawamuraHidechika Okada
Mar 20, 2003·The Journal of Biological Chemistry·John B WalkerLaszlo Bajzar
Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·M Schneider, M Nesheim
Oct 4, 2003·The Journal of Biological Chemistry·Timothy MylesLawrence L K Leung
Dec 9, 2003·The Journal of Biological Chemistry·Pauline F MarxJoost C M Meijers
Aug 18, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Mats StrömqvistDirk Hendriks
Jun 11, 2005·Journal of Thrombosis and Haemostasis : JTH·P F MarxJ C M Meijers
Dec 20, 2005·Journal of Thrombosis and Haemostasis : JTH·A GilsP J Declerck
Apr 6, 2006·The Journal of Biological Chemistry·Erik CeresaAnn Gils
May 5, 2006·Seminars in Thrombosis and Hemostasis·Charles T Esmon
Dec 8, 2007·Circulation Research·Karlien BuelensAnn Gils
May 1, 2008·Analytical Biochemistry·Magdalena WysockaKrzysztof Rolka

❮ Previous
Next ❯

Citations

Dec 21, 2016·Molecular Microbiology·Slawomir LukomskiRita Berisio
Dec 21, 2017·Critical Care Medicine·Fabrizio SemeraroLuciano Gattinoni
May 21, 2018·Journal of Thrombosis and Haemostasis : JTH·T UranoY Suzuki
May 14, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·David Gailani, Andras Gruber
Nov 18, 2018·Hormone Molecular Biology and Clinical Investigation·Sven O Skouby, Johannes J Sidelmann
Jul 17, 2019·Current Drug Targets·Tetsumei UranoFrancis J Castellino
Apr 10, 2018·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Antonio ArauzMiguel A Barboza
Mar 22, 2020·International Journal of Molecular Sciences·J Matthew NicklasPeter K Henke
Jan 31, 2017·Journal of Thrombosis and Haemostasis : JTH·A-C Jönsson RylanderK Wåhlander
Aug 2, 2017·BioMed Research International·Dingeman C Rijken, Shirley Uitte de Willige
Jun 28, 2016·Journal of Thrombosis and Haemostasis : JTH·V Gurewich, R Pannell
Jan 23, 2021·International Journal of Molecular Sciences·Karen ClaesenDirk Hendriks
Nov 3, 2020·Research and Practice in Thrombosis and Haemostasis·Ivan PeyronOlivier D Christophe
May 19, 2018·Chemical Reviews·Joan L ArolasF Xavier Gomis-Rüth
Sep 3, 2021·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christine V OdomLee J Quinton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.